Tags

Type your tag names separated by a space and hit enter

Clinical experience with cefpodoxime proxetil in acute otitis media.
Pediatr Infect Dis J. 1995 Apr; 14(4 Suppl):S12-8.PI

Abstract

Although it varies from country to country, there is a worrying worldwide increase in antibiotic resistance among pathogens causing otitis. This has led to a search for therapeutic alternatives to the reference treatment, which is still amoxicillin in many countries. Cefpodoxime proxetil is one such alternative. Six comparative randomized trials of cefpodoxime proxetil in childhood acute otitis media have been published or presented at international conferences. They involved a total of 1188 patients, 658 of whom received cefpodoxime proxetil and 530 of whom received the comparator drug (amoxicillin/clavulanic acid in 3 trials, cefaclor in 1, and cefixime in 2); duration of treatment varied from 5 days for cefpodoxime proxetil to 10 days for amoxicillin/clavulanic acid, and the age of the children included ranged from 2 months to 12 years. The clinical efficacy of cefpodoxime proxetil was at least equivalent to that of the comparators in 4 trials and significantly better in 2 trials. Firstly, in one study vs. amoxicillin/clavulanic acid, the superiority of cefpodoxime proxetil (8 mg/kg/day twice daily) in terms of healing at the end of treatment and in terms of the number of normal tympanograms at the follow-up visit was shown. Secondly, in a study performed by our group, vs. cefixime, cefpodoxime proxetil (8 mg/kg/day twice daily) showed a better healing rate at the end of treatment in febrile and painful acute otitis media. The microbiologic and pharmacokinetic data show that cefpodoxime proxetil is one of the most active compounds against Haemophilus influenzae and Streptococcus pneumoniae.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Hôpital Intercommunal de Créteil, France.

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Review

Language

eng

PubMed ID

7792125

Citation

Cohen, R. "Clinical Experience With Cefpodoxime Proxetil in Acute Otitis Media." The Pediatric Infectious Disease Journal, vol. 14, no. 4 Suppl, 1995, pp. S12-8.
Cohen R. Clinical experience with cefpodoxime proxetil in acute otitis media. Pediatr Infect Dis J. 1995;14(4 Suppl):S12-8.
Cohen, R. (1995). Clinical experience with cefpodoxime proxetil in acute otitis media. The Pediatric Infectious Disease Journal, 14(4 Suppl), S12-8.
Cohen R. Clinical Experience With Cefpodoxime Proxetil in Acute Otitis Media. Pediatr Infect Dis J. 1995;14(4 Suppl):S12-8. PubMed PMID: 7792125.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical experience with cefpodoxime proxetil in acute otitis media. A1 - Cohen,R, PY - 1995/4/1/pubmed PY - 1995/4/1/medline PY - 1995/4/1/entrez SP - S12 EP - 8 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 14 IS - 4 Suppl N2 - Although it varies from country to country, there is a worrying worldwide increase in antibiotic resistance among pathogens causing otitis. This has led to a search for therapeutic alternatives to the reference treatment, which is still amoxicillin in many countries. Cefpodoxime proxetil is one such alternative. Six comparative randomized trials of cefpodoxime proxetil in childhood acute otitis media have been published or presented at international conferences. They involved a total of 1188 patients, 658 of whom received cefpodoxime proxetil and 530 of whom received the comparator drug (amoxicillin/clavulanic acid in 3 trials, cefaclor in 1, and cefixime in 2); duration of treatment varied from 5 days for cefpodoxime proxetil to 10 days for amoxicillin/clavulanic acid, and the age of the children included ranged from 2 months to 12 years. The clinical efficacy of cefpodoxime proxetil was at least equivalent to that of the comparators in 4 trials and significantly better in 2 trials. Firstly, in one study vs. amoxicillin/clavulanic acid, the superiority of cefpodoxime proxetil (8 mg/kg/day twice daily) in terms of healing at the end of treatment and in terms of the number of normal tympanograms at the follow-up visit was shown. Secondly, in a study performed by our group, vs. cefixime, cefpodoxime proxetil (8 mg/kg/day twice daily) showed a better healing rate at the end of treatment in febrile and painful acute otitis media. The microbiologic and pharmacokinetic data show that cefpodoxime proxetil is one of the most active compounds against Haemophilus influenzae and Streptococcus pneumoniae.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/7792125/Clinical_experience_with_cefpodoxime_proxetil_in_acute_otitis_media_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=7792125.ui DB - PRIME DP - Unbound Medicine ER -